PDLIM2 and lung carcinoma: To investigate the pathogenic and clinical relevance of AM PDLIM2 in lung cancer, we first examined its expression in bronchioalveolar lavage (BAL) cells, of which 90%–95% are AMs (25), from urethane-treated mice.